Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today ...
Biodexa Pharmaceuticals PLC has announced a change in its American Depositary Receipts (ADR) ratio, effective July 31, 2025. The new ratio will be one ADR representing 100,000 ordinary shares, up from ...
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today ...
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces a ratio change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results